Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
Jennifer A. Woyach: Results of Alliance North American Intergroup Study A041202 - YouTube
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
Frontiers | Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Ibrutinib Versus FCR: A "Paradigm Shift" for Younger Patients With Treatment-Naïve CLL
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug | OTT
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia | Trials | Full Text
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
IVO vs IO Phase 3 Trial of the Impact of Adding Venetoclax to Ibrutinib and Obinutuzumab in CLL
Venetoclax regimen not superior to standard therapy alone for older patients with CLL
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial - ScienceDirect
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia | Trials | Full Text
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Management of CLL in 2021 and Beyond - YouTube
RESONATE-2 - Study Design | IMBRUVICA® (ibrutinib) HCP
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia - ScienceDirect
